GXI: Reporting Delays And Accounting Concerns Will Pressure Long Term Confidence

Analysts have trimmed their price targets on Gerresheimer, with one cut from €34.10 to €26.80 contributing to a modest reduction in the modelled fair value from €24.40 to about €23.37, as concerns around delayed results, accounting issues, and the Bormioli overhang weigh on sentiment.

Analyst Commentary

Recent research has shifted toward a more cautious stance on Gerresheimer, with several firms moving to neutral ratings and cutting price targets to around €26.80 from about €34.10. The key themes revolve around valuation risk, execution on reporting and accounting, and uncertainty tied to the Bormioli transaction and broader market overhangs.

Bullish Takeaways

Even after cuts, some bullish analysts still see upside to current trading levels based on their revised fair value estimates around €26.80, which they compare to the modelled fair value of roughly €23.37 referenced earlier.
The use of detailed valuation models that explicitly factor in delayed results and accounting questions suggests that part of the perceived risk is now reflected in published targets. This can limit further downside in those models if execution stabilises.
References to "persistent market overhangs" imply that some concerns are sentiment driven rather than purely fundamental, leaving room for sentiment to improve if disclosures and reporting timelines become more predictable.

Bearish Takeaways

Bearish analysts are concerned that delayed results and accounting issues introduce execution risk. They treat this as a reason to step back from more optimistic ratings and shift to Hold stances.
The Bormioli overhang and broader "persistent market overhangs" are seen as headwinds for valuation, as they create uncertainty around how quickly the stock can close the gap between trading price and revised targets.
Price target cuts from about €34.10 to €26.80, and the modelled fair value move from €24.40 to roughly €23.37, signal that analysts are reassessing both growth assumptions and risk premia embedded in their models.
Repeated downgrades over a short period point to limited conviction on near term execution. Bearish analysts prefer to wait for clearer evidence on reporting timelines and the resolution of accounting questions before revisiting more positive ratings.

What's in the News

Gerresheimer rejected a takeover bid from Silgan, according to Reuters. This keeps Gerresheimer independent and leaves open questions around future corporate interest and potential deal terms. Source: Reuters.
Newel Health entered into a partnership with Gerresheimer to support pharma and biotech clients in developing digital endpoints, digital medical devices, and integrated drug plus digital solutions. The partnership combines Newel Health’s H-Core platform and AI tools with Gerresheimer’s drug delivery and primary packaging capabilities. Source: Key Developments.
Under the Newel Health partnership, Gerresheimer is involved in projects that use connected devices, software as a medical device, and secure data infrastructure to generate real world data and AI driven insights for clinical development and commercialization. Source: Key Developments.
Gerresheimer AG was removed from the Germany SDAX (Total Return) Index, which may affect how some index linked funds and mandates approach the stock. Source: Index Constituent Drops.

Valuation Changes

Fair Value: modelled fair value moved slightly lower from €24.40 to about €23.37.
Discount Rate: the discount rate used in the model is broadly unchanged, moving from 10.19% to about 10.20%.
Revenue Growth: the assumed long term revenue growth rate remains effectively stable at about 5.42%.
Net Profit Margin: the modelled net profit margin is essentially flat at roughly 3.95%.
Future P/E: the assumed future P/E multiple has been reduced from about 10.65x to roughly 10.20x.

5 views

Key Takeaways

The acquisition of Bormioli Pharma and new product lines are expected to significantly boost Gerresheimer's revenue and profitability.
Strategic facility upgrades and a shift to high-value products aim to enhance margins and improve overall earnings.
Potential integration risks from Bormioli Pharma acquisition and ongoing financial challenges could affect Gerresheimer's liquidity, margins, and operational stability.

Catalysts

About Gerresheimer

Manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally.What are the underlying business or industry changes driving this perspective?

The acquisition of Bormioli Pharma is expected to propel Gerresheimer's revenues from €2 billion in 2024 to around €2.5 billion in 2025, while also enhancing the company's adjusted EBITDA margin to approximately 22%. This marks a significant step forward in terms of revenue growth and profitability enhancement.
The anticipated organic growth rate of 3% to 5% in 2025, driven by new product lines, a shift towards high-value products, and normalization of operations at facilities affected by prior disruptions, is poised to positively impact Gerresheimer's revenue and profitability.
The ramping up of new production lines in Skopje and Peachtree City, and the introduction of advanced products such as ready-to-fill syringes and vials, indicates a move towards higher-margin products which is expected to improve net margins and earnings.
The strategic transitions and capacity expansions at key facilities like the new state-of-the-art hybrid furnace in Lohr, and the restoration of full capacity at Morganton, are likely to enhance production efficiency and contribute positively to future earnings.
The ongoing trend towards high-value product offerings, such as the shift from standard bulk vials to high-value vials, is positioned to strengthen net margins and improve overall earnings due to superior pricing and market demand for innovative solutions.

Gerresheimer Earnings and Revenue Growth

Gerresheimer Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Gerresheimer's revenue will grow by 5.4% annually over the next 3 years.
Analysts assume that profit margins will increase from 1.0% today to 4.0% in 3 years time.
Analysts expect earnings to reach €104.2 million (and earnings per share of €3.01) by about June 2029, up from €23.4 million today. However, there is some disagreement amongst the analysts with the more bullish ones expecting earnings as high as €167.6 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 10.4x on those 2029 earnings, down from 40.1x today. This future PE is lower than the current PE for the GB Life Sciences industry at 40.2x.
Analysts expect the number of shares outstanding to remain consistent over the next 3 years.
To value all of this in today's terms, we will use a discount rate of 10.2%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The integration of Bormioli Pharma presents potential integration risks and associated costs, which could impact overall operational efficiency and margins.
There is significant seasonal fluctuation in cash flow, with Q1 often showing negative free cash flow figures, which could stress liquidity and financial stability if not managed prudently.
Ongoing challenges in the moulded glass sector, including decreased demand in the cosmetics market, could negatively impact revenues and operational stability in the short term.
The company's increased leverage due to the acquisition of Bormioli could, if not carefully managed, lead to financial strain, impacting earnings and investor confidence.
Delays and disruptions, such as those from natural disasters affecting Morganton, could introduce further operational risks, impacting revenue streams and margins.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of €23.37 for Gerresheimer based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of €46.0, and the most bearish reporting a price target of just €12.5.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be €2.6 billion, earnings will come to €104.2 million, and it would be trading on a PE ratio of 10.4x, assuming you use a discount rate of 10.2%.
Given the current share price of €27.08, the analyst price target of €23.37 is 15.9% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Gerresheimer?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Ongoing Uncertainties And Downgrades Will Shape Efficiency Efforts Ahead